Drug-Resistant Epilepsy in Tuberous Sclerosis Complex

Status: draft · Last updated 2026-11-17 · By Jason S. Hauptman, MD, PhD (AI-assisted)

Read in the interactive book →

High-yield points

  • Epilepsy in 70–90%; drug-resistant epilepsy concentrates in TSC2 .
  • Prevention trials disagree:
    • EPISTOP: preventive vigabatrin delayed seizures and reduced drug-resistant epilepsy ;
    • PREVeNT: no cognitive or epilepsy benefit, but fewer spasms .
    • Screen infants with EEG .
  • Everolimus (EXIST-3): 40% responders at high trough vs 15% on placebo .
  • Surgery works in selected children: about 66–69% good outcomes . Predictors differ between meta-analyses: EEG–MRI concordance and a single visible tuber favor a good outcome .
    • Multiplicity of tubers is not an automatic exclusion.
  • Options: tuberectomy (with peri-tuberal margin), lobar or multilobar resection, LITT, callosotomy, VNS.

Landmark papers

  • EXIST-3 (French et al., Lancet 2016): a phase 3 randomized trial (366 patients) of adjunctive everolimus. Responders were 40% at high trough vs 15% on placebo .
  • EPISTOP (Kotulska et al., Ann Neurol 2021): preventive vigabatrin at the first epileptiform EEG delayed the first seizure and reduced drug-resistant epilepsy at 24 months (OR 0.23) .
  • Hale et al., J Neurosurg Pediatr 2025: an individual-participant meta-analysis of 1,338 children after epilepsy surgery. 66% had a good outcome, and 1 or fewer visible tubers predicted success .

Between 70% and 90% of children with tuberous sclerosis complex (TSC) develop epilepsy, frequently drug-resistant .

Jason S. Hauptman, MD, PhD© 2026 Jason S. Hauptman, MD, PhD. All rights reserved. Original figure from Hauptman's High Yield Thoughts in Pediatric Neurosurgery (pedsneurosurg.org). Do not copy, reproduce, redistribute or adapt without written permission.https://www.pedsneurosurg.org/hy-peds-ns:tsc_epilepsy:9d34090b2fec5d2b© 2026 Jason S. Hauptman, MD, PhD. All rights reserved. Original figure; please do not copy, reproduce or redistribute without written permission.Lateral left hemisphere with several tubers and one epileptogenic tuber, with a zoomed section showing calcification, a cystic-like core, dysplastic cortex, a radial band and a peri-tuberal margin; a pathway from infant EEG surveillance through vigabatrin and everolimus to surgical evaluation and stereo-EEG; and tuberectomy, lobar resection, laser ablation, callosotomy and VNS(A) MULTIPLE TUBERS; ONE EPILEPTOGENIC (LEFT HEMISPHERE, LATERAL)non-epileptogenictubersepileptogenic tuber(seizure onset)cystic-like corecalcificationthick dysplastic cortexradial white-matter bandperi-tuberal margin(B) PATHWAYInfant EEG surveillancebefore seizures; treatearly dischargesVigabatrin first line(spasms, focal); theneverolimus, other ASMsSurgical evaluationvideo-EEG, MRI, PET /MEG, SPECTStereo-EEGif discordant; repeatif multifocal(C) SURGICAL OPTIONSTuberectomywith peri-tuberal marginLobar resectionmultiple tubers in a lobeLaser ablationdeep or small tuberCallosotomypalliative: drop attacksVNSpalliative
Epilepsy in TSC. (a) Several cortical tubers, one of them the epileptogenic focus, with calcification and a cystic core, and the peri-tuberal cortex around it. (b) Pathway from early EEG surveillance through vigabatrin, everolimus and other medicines to surgical evaluation: scalp video-EEG, MRI, PET or MEG, then stereo-EEG or grids when needed. (c) Surgical options: tuberectomy with peri-tuberal margin, lobar or multilobar resection, laser ablation of a deep tuber, and palliative options (callosotomy, VNS). Not to scale.

Who is at risk

Prevention in infancy

Medical therapy

Surgical evaluation

Surgical options

Beyond TSC: mTOR inhibition in refractory epilepsy

Related topics

References

  1. Kotulska K, Kwiatkowski DJ, Curatolo P, et al. Prevention of epilepsy in infants with tuberous sclerosis complex in the EPISTOP trial. Ann Neurol 2021;89(2):304–314. doi:10.1002/ana.25956. PMID 33180985. verified
  2. Fallah A, Guyatt GH, Snead OC, et al. Predictors of seizure outcomes in children with tuberous sclerosis complex and intractable epilepsy undergoing resective epilepsy surgery: an individual participant data meta-analysis. PLoS One 2013;8(2):e53565. doi:10.1371/journal.pone.0053565. PMID 23405072. verified
  3. Uchitel J, Fariyike O, Steeman S, et al. Utility of repeat stereotactic EEG in pediatric patients with tuberous sclerosis. Epilepsia Open 2026;11(5):1465–1477. doi:10.1002/epi4.70293. PMID 42400368. verified
  4. Farach LS, Richard MA, Wulsin AC, et al. Drug-resistant epilepsy in tuberous sclerosis complex is associated with TSC2 genotype: more findings from the Preventing Epilepsy Using Vigabatrin (PREVeNT) trial. Pediatr Neurol 2024;159:62–71. doi:10.1016/j.pediatrneurol.2024.06.012. PMID 39142021. verified
  5. Bebin EM, Peters JM, Porter BE, et al. Early treatment with vigabatrin does not decrease focal seizures or improve cognition in tuberous sclerosis complex: the PREVeNT trial. Ann Neurol 2024;95(1):15–26. doi:10.1002/ana.26778. PMID 37638552. verified
  6. Northrup H, Aronow ME, Bebin EM, et al. Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations. Pediatr Neurol 2021;123:50–66. doi:10.1016/j.pediatrneurol.2021.07.011. PMID 34399110. verified
  7. French JA, Lawson JA, Yapici Z, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet 2016;388(10056):2153–2163. doi:10.1016/S0140-6736(16)31419-231419-2). PMID 27613521. verified
  8. Hale AT, Savage C, Estevez-Ordonez D, et al. Epilepsy surgery outcomes in children with tuberous sclerosis complex: a systematic review and meta-analysis. J Neurosurg Pediatr 2025;35(6):599–611. doi:10.3171/2024.12.PEDS24311. PMID 40215622. verified
  9. Hall K, Saneto R, Randle S, et al. Phase 1 study of ABI-009 (nab-rapamycin) for surgically refractory epilepsy (RaSuRE). Epilepsia 2025;66(11):4246–4258. doi:10.1111/epi.18555. PMID 40682748. verified

Verification (2026-11-17):

Caveats: